Opendata, web and dolomites

INTEGRATA SIGNED

Integrating chemical and biological approaches to target NAD production and signaling in cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 INTEGRATA project word cloud

Explore the words cloud of the INTEGRATA project. It provides you a very rough idea of what is the project "INTEGRATA" about.

broad    toxicity    nucleotide    metabolic    geared    promotion    proof    fuel    downstream    exchange    pharma    oncogenic    plan    signaling    preclinical    exerting    overarching    demands    dna    models    phd    cell    autocrine    extracellular    space    centres    integrata    agents    producing    skills    interdisciplinary    expertise    biotech    cancers    inhibitors    repair    applicability    naprt    of    intense    academic    adenine    underlies    nicotinamide    networking    pro    nicotinic    utilizing    newly    pharmacology    participation    haematological    nampt    biosynthetic    training    escape    cancer    enzymes    deregulated    shared    de    scientific    appear    paracrine    encompasses    motility    smes    biosynthesis    nad    vivo    immune    therapeutics    14    proven    events    transferrable    students    public    active    differentiation    moonlight    joint    phosphoribosyltransferase    cells    upregulated    solid    acid    train    carcinogenesis    education    dinucleotide    infrastructures    courses    roles    intersectoral   

Project "INTEGRATA" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI GENOVA 

Organization address
address: VIA BALBI 5
city: GENOVA
postcode: 16126
website: www.unige.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 3˙738˙573 €
 EC max contribution 3˙738˙573 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2018
 Funding Scheme MSCA-ITN-ETN
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2022-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI GENOVA IT (GENOVA) coordinator 522˙999.00
2    THE UNIVERSITY OF SHEFFIELD UK (SHEFFIELD) participant 303˙172.00
3    CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CH (LAUSANNE) participant 281˙276.00
4    NOVIMMUNE SA CH (PLAN LES OUATES GENEVE) participant 281˙276.00
5    UNIVERSITE DE GENEVE CH (GENEVE) participant 281˙276.00
6    UNIVERSITE DE MONTPELLIER FR (MONTPELLIER) participant 274˙802.00
7    INNOVAMOL CONSULTING SRL IT (MODENA) participant 261˙499.00
8    UNIVERSITA DEGLI STUDI DI TORINO IT (TORINO) participant 261˙499.00
9    UNIVERSITA DEGLI STUDI DI TRENTO IT (TRENTO) participant 261˙499.00
10    HEIDELBERG PHARMA RESEARCH GMBH DE (LADENBURG) participant 252˙788.00
11    UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF DE (HAMBURG) participant 252˙788.00
12    UNIVERSITATSKLINIKUM BONN DE (BONN) participant 252˙788.00
13    UNIVERSIDAD DE SEVILLA ES (SEVILLA) participant 250˙904.00
14    INNOVATION ACTA S.R.L. IT (ROMA) partner 0.00
15    UNIVERSITE DE LAUSANNE CH (LAUSANNE) partner 0.00

Map

 Project objective

Deregulated nicotinamide adenine dinucleotide (NAD) biosynthesis and signaling underlies many aspects of carcinogenesis. NAD biosynthetic enzymes, such as nicotinamide phosphoribosyltransferase (NAMPT) and nicotinic acid phosphoribosyltransferase (NAPRT), are commonly upregulated in cancer cells, where they fuel increased metabolic demands and downstream enzymes involved in DNA repair and in the promotion of cell growth, cell motility, de-differentiation and immune escape. In addition, NAD-producing enzymes, such as NAMPT, moonlight in the extracellular space, exerting strongly pro-oncogenic, autocrine and paracrine effects. Many of these roles of NAD-producing and NAD-utilizing enzymes appear to be shared between solid and haematological cancers. Thus, agents targeting NAD production or signaling are expected to have broad applicability. INTEGRATA will: 1. develop new NAD biosynthesis and NAD/nucleotide signaling inhibitors; 2. assess pharmacology and toxicity of the new therapeutics in preclinical models; 3. achieve the proof-of-concept of activity of the newly generated agents in relevant in vivo cancer models. INTEGRATA will train 14 PhD students in an overarching, interdisciplinary training programme that will include training-by-research, joint courses of technical, scientific, and transferrable skills, active participation to public scientific events, and an intense intersectoral networking exchange plan. The INTEGRATA Consortium encompasses academic institutions, research centres, and SMEs/biotech pharma, all with proven experience in higher education and training, and geared with state-of-the-art scientific and technical expertise and infrastructures.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INTEGRATA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INTEGRATA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

EAGRE (2020)

Eagre/Aegir: high-seas wave-impact modelling

Read More  

SuperCol (2020)

SuperCol: Rational design of super-selective and responsive colloidal particles for biomedical applications

Read More  

ApPEARS (2019)

Appearance Printing - European Advanced Research School

Read More